Hepatitis B News and Research

Latest Hepatitis B News and Research

Updated HIV treatment guidelines may benefit individuals infected with HIV: Researchers

Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.

8 Jun 2010

HIV & Hepatitis scare after endoscopy at a Warrawong Clinic

The South-Eastern Sydney Illawarra Health Service claims that the risk of contracting blood borne serious viral infections like HIV and Hepatitis are low among patients who had an endoscopy done at a private Warrawong clinic. This clinic came under into the spotlight after investigations started to detect the cause of illness in nine persons who underwent endoscopy. The facility is at Cowper Street, Warrawong run by Dr Zakaria Lakhany and is presently closed.

7 Jun 2010

Cytheris completes €12 million Series D financing

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has completed a €12 million ($15 million) Series D financing.

7 Jun 2010

Case report on clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

3 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

HTDS commences clinical trials for MEVAC-A vaccine in Vietnam

Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.

2 Jun 2010

Hepatitis C investigations intensify as number of women infected by doctor rises

In recent news 12 women had been infected with the Hepatitis C virus allegedly from an anaesthetist Dr James Latham Peters, practising at an abortion clinic, Croydon Day Surgery. As the investigations continue the number of infected women has risen to 44.

1 Jun 2010

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Nihal Altan-Bonnet, assistant professor of cell biology, Rutgers University in Newark, and her research team have made a significant new discovery about RNA viruses and how they replicate themselves.

29 May 2010

State roundup: Employees' insurance rates, a hospital merger, Florida and Mass. public health issues

Today's roundup of state news includes changes in insurance rates for Kansas state employees, problems with EMT certification in Massachusetts and a hospital merger in the Washington D.C. area.

29 May 2010

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

Infectious diseases specialist Dr Marc Pellegrini from the Walter and Eliza Hall Institute will today receive the Frank Fenner Award from the Australasian Society for Infectious Diseases, recognising Dr Pellegrini's efforts to understand human responses to chronic infections.

28 May 2010

New treatment benefits patients with advanced liver disease due to HCV infection: Researchers

Researchers at the UCLA Medical Center found that antiviral therapy during compensated cirrhosis, when compared with all other strategies, is the most cost-effective approach to treating patients with advanced liver disease due to hepatitis C infection. Full details appear in the June issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 May 2010

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. The Elecsys Anti-HCV assay is an in-vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma.

From Roche Sequencing and Life Science 28 May 2010

PCA-Rx represents next generation of chelation technology for ASD patients

According to the Center for Disease Control, autism has risen to an epidemic rate of 1 in 100 in the U.S., up from 1 in 150 in 2007. While controversy looms regarding its cause, many parents of autistic children believe a correlation exists with toxin accumulation. To give autism spectrum disorder sufferers a natural alternative to chelation therapy, Maxam Nutraceutics has introduced PCA-Rx.

28 May 2010

HZI researchers develop new method to produce insulin for treatment of diabetes

More than eight million diabetics live in Germany. Diabetes is not restricted to our prosperous society and the highest growth rates often occur in countries with aspiring economies such as in Asia. Worldwide, more than 285 million people suffer from this illness; with 50 million diabetics, India is the country with the most people affected by this disease.

27 May 2010

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.

26 May 2010

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

Italian researchers have discovered that antiviral treatment and sustained virologic response prevents esophageal varices in patients with compensated hepatitis C -induced cirrhosis, indicating that endoscopic surveillance can be safely delayed or avoided in these patients. Full findings are published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

26 May 2010

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

A study conducted by researchers at the Cleveland Clinic finds that patients suffering from cirrhosis preceded by nonalcoholic steatohepatitis are at an equal risk of developing hepatocellular carcinoma than those who develop cirrhosis resulting from hepatitis C virus. Results of this study appear in the June issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Biomagnetics Diagnostics presents new series of videos on world's first handheld Integrated Optical Biosensor

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the availability of a new series of video taped interviews of CEO, Clayton Hardman where he presents the world's first handheld Integrated Optical Biosensor (IOBS), which was recently licensed under an agreement with Los Alamos National Security LLC.

25 May 2010

Hepatitis B News and Research

Latest Hepatitis B News and Research

Updated HIV treatment guidelines may benefit individuals infected with HIV: Researchers

HIV & Hepatitis scare after endoscopy at a Warrawong Clinic

Cytheris completes €12 million Series D financing

Case report on clear cell ICC

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

HTDS commences clinical trials for MEVAC-A vaccine in Vietnam

Hepatitis C investigations intensify as number of women infected by doctor rises

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

State roundup: Employees' insurance rates, a hospital merger, Florida and Mass. public health issues

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

New treatment benefits patients with advanced liver disease due to HCV infection: Researchers

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

PCA-Rx represents next generation of chelation technology for ASD patients

HZI researchers develop new method to produce insulin for treatment of diabetes

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Biomagnetics Diagnostics presents new series of videos on world's first handheld Integrated Optical Biosensor

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Hepatitis B News and Research

Latest Hepatitis B News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in